Intradermal vaccination with hollow microneedles: a comparative study of various protein antigen and adjuvant encapsulated nanoparticles by Du, G. et al.
Contents lists available at ScienceDirect
Journal of Controlled Release
journal homepage: www.elsevier.com/locate/jconrel
Intradermal vaccination with hollow microneedles: A comparative study of
various protein antigen and adjuvant encapsulated nanoparticles
Guangsheng Dua, Rania M. Hathouta,b, Maha Nasra,b, M. Reza Nejadnika, Jing Tuc,
Roman I. Koningd, Abraham J. Kosterd, Bram Slüttera,e, Alexander Krosc, Wim Jiskoota,
Joke A. Bouwstraa,⁎, Juha Mönkärea
a Division of Drug Delivery Technology, Cluster BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
b Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
c Department of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
d Department of Molecular Cell Biology, Section Electron Microscopy, Leiden University Medical Center, Leiden University, Leiden, The Netherlands
e Division of Biopharmaceutics, Cluster BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
A R T I C L E I N F O
Keywords:
Intradermal vaccination
Hollow microneedles
Nanoparticles
Antigen
Adjuvant
A B S T R A C T
In this study, we investigated the potential of intradermal delivery of nanoparticulate vaccines to modulate the
immune response of protein antigen using hollow microneedles. Four types of nanoparticles covering a broad
range of physiochemical parameters, namely poly (lactic-co-glycolic) (PLGA) nanoparticles, liposomes, meso-
porous silica nanoparticles (MSNs) and gelatin nanoparticles (GNPs) were compared. The developed nano-
particles were loaded with a model antigen (ovalbumin (OVA)) with and without an adjuvant (poly(I:C)), fol-
lowed by the characterization of size, zeta potential, morphology, and loading and release of antigen and
adjuvant. An in-house developed hollow-microneedle applicator was used to inject nanoparticle suspensions
precisely into murine skin at a depth of about 120 μm. OVA/poly(I:C)-loaded nanoparticles and OVA/poly(I:C)
solution elicited similarly strong total IgG and IgG1 responses. However, the co-encapsulation of OVA and poly
(I:C) in nanoparticles significantly increased the IgG2a response compared to OVA/poly(I:C) solution. PLGA
nanoparticles and liposomes induced stronger IgG2a responses than MSNs and GNPs, correlating with sustained
release of the antigen and adjuvant and a smaller nanoparticle size. When examining cellular responses, the
highest CD8+ and CD4+ T cell responses were induced by OVA/poly(I:C)-loaded liposomes. In conclusion, the
applicator controlled hollow microneedle delivery is an excellent method for intradermal injection of nano-
particle vaccines, allowing selection of optimal nanoparticle formulations for humoral and cellular immune
responses.
1. Introduction
Skin is an attractive administration site for immunization and may
act as an excellent alternative for traditional intramuscular or sub-
cutaneous vaccination. Furthermore, intradermal vaccination may en-
able dose sparing, since the skin has a rich network of immune cells
compared to muscle or subcutaneous tissue [1]. However, the upper-
most layer of the skin, the stratum corneum, is the main barrier that
prevents the transport of vaccines (> 500 Da) across the skin. There-
fore, novel delivery methods need to be developed. Among various
methods developed for antigen delivery via the skin, especially micro-
needle-based approaches have recently attracted increasing attention
[2]. The major advantage of microneedles is their ability to pierce the
skin in a minimally invasive manner and subsequently deliver their
payload in the superficial skin layers potentially without pain, owing to
the limited penetration depth of microneedles (typically< 500 μm)
[3].
Several microneedle types have been developed for vaccine de-
livery, such as coated or dissolving microneedles which can release the
dry antigen into the epidermis and dermis after the piercing of the skin
[2]. In contrast, hollow microneedles can be used to deliver antigens or
particulate formulations as solutions or suspensions into the skin. To
this end, in our group a hollow microneedle device has been developed
that allows precise and controlled injections into the epidermis and
dermis by using etched fused-silica capillary-based microneedles [4–6].
The advantage of the hollow microneedles compared to dissolving or
coated microneedles is that little time is required for modifying the
dose, formulation or administration depth. This is particularly
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advantageous when studying optimization of formulations or para-
meters for the immunization (e.g. penetration depth or vaccine dose).
Furthermore, if required, a higher dose can be injected into the skin
compared to dissolving and coated microneedles.
Subunit antigens are based on purified antigens and are regarded
safer than traditional whole bacterium- or virus-based vaccines [7].
However, these antigens have often lower immunogenicity and there-
fore adjuvants, such as toll-like receptor (TLR) ligands or toxoids, are
needed to increase the immune response [8]. Recently, nanoparticles
have gained growing attention for the delivery of subunit vaccines
because of their capability of protecting antigens from degradation,
forming a depot at the site of injection, and facilitating antigen uptake
by dendritic cells (DCs) [9–11]. Studies have additionally shown that
co-formulation of antigen and adjuvant into a nanoparticle might be
crucial to improve immune responses against subunit vaccines [12–15].
However, it is not well understood how the physicochemical properties
such as size, material, surface charge or release behavior of antigen/
adjuvant influence the immune response. Previously, it has been pro-
posed that positively charged nanoparticles with a size smaller than
about 200 nm might be optimal for the interaction with antigen-pre-
senting cells [9,16–18]. Moreover, sustained release of antigen and
adjuvant from nanoparticles and a depot effect of nanoparticles on the
cell surface could allow the co-delivery of antigen and adjuvant to
antigen-presenting cells [17,19]. However, most vaccination studies
have been performed by intramuscular or subcutaneous injection and
no studies have directly compared different nanoparticles for in-
tradermal vaccine delivery.
The aim of this study was to assess the potential of antigen loaded
nanoparticles, with or without co-encapsulated adjuvant, to induce
humoral and cellular immune responses after hollow microneedle-
mediated intradermal immunization. To this end, we prepared four
different nanoparticulate delivery systems with varying physicochem-
ical properties, namely poly (lactic-co-glycolic) acid (PLGA) nano-
particles, liposomes, mesoporous silica nanoparticles (MSNs) and ge-
latin nanoparticles (GNPs). PLGA nanoparticles [10,20–24] and
liposomes [12,18,22,25] have been extensively investigated as bio-
compatible and biodegradable nanoparticle vaccine delivery systems.
MSNs gain increasing attention for vaccine delivery because of their
controlled size and mesostructure, excellent in vivo biocompatibility
and high loading capacity [26,27]. Gelatin based nanoparticles have
been studied as promising vaccine carriers because of their excellent
biocompatibility, stability and aptness for surface modification
[28–30].
A model antigen, ovalbumin (OVA), with and without a TLR3
agonist, poly(I:C), was encapsulated into the nanoparticles. First, the
physicochemical properties and the in vitro release of antigen and ad-
juvant of the different nanoparticulate formulations were characterized.
Next, mice were immunized with the formulations by using a hollow
microneedle device followed by the analysis of humoral and cellular
immune responses. The results reveal that the immune response de-
pends on encapsulation of antigen/adjuvant and the characteristics of
nanoparticles. Furthermore, we demonstrate that the hollow micro-
needles together with the applicator are excellent tools for intradermal
vaccination and screening of nanoparticulate formulations.
2. Materials and methods
2.1. Materials
PLGA (acid terminated, lactide glycolide 50:50, Mw 24–38 kDa),
gelatin from porcine skin (bloom 300), OVA for in vitro studies (albumin
from chicken egg white, lyophilized), bovine serum albumin (BSA)
≥96%, gluteraldehyde, glycine, cholamine chloride hydrochloride (2-
aminoethyl)-trimethylammoniumchloride hydrochloride, 1-ethyl-3-(3-
dimethyl-aminopropyl) carbodiimide hydrochloride (EDC), cholesterol
(≥99%) and hydrofluoric acid ≥48% were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Polyvinyl alcohol (PVA) 4–88
(31 kDa) and ethylenediaminetetraacetic acid (EDTA) were purchased
from Fluka (Steinheim, Germany). 1-step™ ultra 3,3′,5,5′-&#132;tetra-
methylbenzidine (TMB) was obtained from Thermo-Fisher Scientific
(Waltham, MA). Endotoxin-free OVA, polyinosinic-polycytidylic acid
(poly(I:C)) (low molecular weight) and its rhodamine-labeled version
were purchased from Invivogen (Toulouse, France). Egg phosphati-
dylcholine (EggPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
1,2-dioleoyl-sn-glycero-3-[phosphor-L-serine](sodium salt) (DOPS), 1,2-
dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) and
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were ordered
from Avanti Polar Lipids (Alabaster, AL). HRP-conjugated goat anti-
mouse total IgG, IgG1 and IgG2a were purchased from Southern
Biotech (Birmingham, AL). Fluorescently labeled antibodies specific for
CD4, CD8 and CD45.1 were ordered from eBioscience (San Diego, The
Netherlands). Sulfuric acid (95–98%) was obtained from JT Baker
(Deventer, The Netherlands). Ethyl acetate and silicone oil (AK350)
were ordered from Boom Chemicals (Meppel, The Netherlands).
Dimethylsulfoxide (DMSO) was ordered from Biosolve BV
(Valkenswaard, The Netherlands). Sodium dodecyl sulfate (SDS) was
purchased from Merck Millipore (Hohenbrunn, Germany). Vivaspin 2
centrifugal concentrators (PES membrane, MWCO 1000 kDa) were
obtained from Sartorius Stedim (Nieuwegein, The Netherlands). Sterile
phosphate buffered saline (PBS, 163.9 mM Na+, 140.3 mM Cl−,
8.7 mM HPO42−, 1.8 mM H2PO4−, pH 7.4) was obtained from Braun
(Oss, The Netherlands). Cell culture medium was prepared by mixing
Roswell Park Memorial Institute medium (RPMI) with 10% Fetal bovine
serum (FBS), 1% L-glutamine and 1% Penicillin-streptamycin. 1 mM
phosphate buffer (PB, 0.77 mM Na2HPO4, 0.23 mM NaH2PO4, pH 7.4),
10 mM PB (7.7 mM Na2HPO4, 2.3 mM NaH2PO4, pH 7.4), 5 mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES, pH 7.4) buffer,
lysis buffer (150 mM ammonium chloride, 10 mM KHCO3, 0.1 mM
EDTA, pH 7.2), and FACS buffer (2% FBS in PBS, pH 7.4) were prepared
in the lab. All the other chemicals used are of analytical grade and Milli-
Q water (18 MΩ/cm, Millipore Co.) was used for the preparation of all
solutions.
2.2. Preparation of nanoparticles
2.2.1. Preparation of PLGA nanoparticles
OVA loaded PLGA nanoparticles (PLGA-OVA) were prepared by
double emulsion with solvent evaporation method as previously re-
ported with modifications [31]. Briefly, 75 μl OVA (20 mg/ml) in PBS
was dispersed in 1 ml ethyl acetate containing 25 mg/ml PLGA by using
a Branson sonifier 250 (Danbury, CT) for 15 s with a power of 20 W.
The obtained water-in-oil emulsion was emulsified with 2 ml aqueous
solution containing 2% (w/v) PVA with the sonifier (15 s, 20 W). The
water-in-oil-in-water double emulsion was added dropwisely into 25 ml
0.3% (w/v) PVA (40 °C) under stirring. The ethyl acetate was evapo-
rated by a rotary evaporator (Buchi rotavapor R210, Flawil, Switzer-
land) for 3 h (150 mbar, 40 °C). The nanoparticles were collected by
centrifugation (Avanti™ J-20XP centrifuge, Beckman Coulter, Brea, CA)
at 35000 g for 10 min. Finally, they were washed twice with 1 mM PB
to remove the excess OVA and PVA and dried in an ice condenser
(Alpha 1–2, Osterode, Germany) in freeze vacuum (−49 °C, 90 mbar)
overnight for further use and storage.
To prepare OVA and poly(I:C) co-encapsulated PLGA nanoparticles
(PLGA-OVA-PIC), 18.75 μl OVA (40 mg/ml) and 75 μl poly(I:C)
(46.7 mg/ml, including 0.03% fluorescently labeled equivalent) were
emulsified with 1 ml PLGA (25 mg/ml) in ethyl acetate to obtain the
water-in-oil emulsion. The rest of the procedure was identical to that of
PLGA-OVA.
2.2.2. Preparation of liposomes
Liposomes were prepared by a film hydration method [32]. A thin
lipid film of EggPC: DOPE: DOTAP in a molar ratio of 9:1:2.5 was
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created by evaporating chloroform of lipid stock solutions (25 mg/ml)
using a rotary evaporator (Buchi rotavapor R210, Flawil, Switzerland).
To prepare OVA loaded liposomes (Lipo-OVA), the lipid film was re-
hydrated in 10 mM PB (pH 7.4) containing 0.25 mg/ml OVA, and
subsequently stabilized at room temperature for 1 h, resulting in final
lipid concentration of 12.5 mg/ml. In the case of OVA and poly(I:C) co-
encapsulated liposomes (Lipo-OVA-PIC), after lipid film hydration,
250 μl poly(I:C) solution (1.32 mg/ml, containing 0.5% rhodamine-la-
beled poly(I:C)) was added slowly (2 μl/min) by using a syringe pump
to the liposome suspension under stirring. Finally, the liposomes were
extruded (LIPEX™ extruder, Northern Lipids, Burnaby, Canada) four
times through a carbonate filter with a pore size of 400 nm and another
four times through a filter with a pore size of 200 nm (Nucleopore
Millipore, Amsterdam, The Netherlands). The obtained suspensions
were transferred into VivaSpin 2 centrifuge concentrators (1000 kDa
MWCO) and centrifuged (Allegra X-12R, Beckman Coulter, In-
dianapolis, IN) twice for 7–8 h (350 g, 22 °C) to remove the excess OVA
and poly(I:C) [18]. The liposome suspensions were collected and stored
at 4 °C until further use.
2.2.3. Preparation of MSNs
Large pore MSNs were synthesized and used for the loading of an-
tigen and adjuvant as described earlier [33]. To improve the colloidal
stability of antigen loaded MSNs, negatively charged liposomes were
fused to the surface of MSNs, as reported previously [34,35]. For this
purpose liposomes were prepared by dispensing stock solutions of
DOPC (70 μl, 25 mg/ml), DOPS (20 μl, 12.5 mg/ml) and cholesterol
(10 μl, 25 mg/ml) in chloroform into scintillation vials. A lipid film was
created by slow evaporation of chloroform in the vial under a nitrogen
flow and dried in vacuum overnight. The lipid film was rehydrated by
the addition of 1 ml of 1 mM PB (pH 7.4) and the mixture was vortexed
for 10 s to form a cloudy lipid suspension. The obtained suspension was
sonicated in a water bath for 10 min. The resulting clear liposome
dispersions were stored at 4 °C for further use.
To prepare lipid bilayer coated and OVA encapsulated MSNs (LB-
MSN-OVA), OVA (0.5 ml, 0.25 mg/ml) in 1 mM PB (pH 7.4) was first
transferred into a 2 ml micro-centrifuge tube, followed by the addition
of MSNs (0.5 ml, 1 mg/ml) and liposomes (0.5 ml, 2 mg/ml). For OVA
and poly(I:C) co-encapsulated and lipid coated MSNs (LB-MSN-OVA-
PIC), 0.5 ml solution containing 0.25 mg/ml OVA and 0.094 mg/ml
poly(I:C) (containing 1.2% rhodamine-labeled poly(I:C)) were mixed
with MSNs and liposomes similarly to LB-MSN-OVA. The resulting
mixtures were incubated for 1.5 h under shaking (400 rpm, 25 °C). The
nanoparticles were collected and excess liposomes, OVA and poly(I:C)
were removed by centrifuging the sample (9000 g, 5 min) with a Sigma
1–15 centrifuge (Osterode, Germany). The obtained nanoparticles were
stored at 4 °C before the use.
2.2.4. Preparation of GNPs
GNPs were prepared by using a two-step desolvation method as
previously described [36]. First, 1.25 g gelatin (cationic, pI 7–9) was
dissolved in 25 ml ultrapure water at 50 °C while stirring at 600 rpm for
30 min. The first desolvation step was carried out by addition of 25 ml
acetone. The mixture was left for 1 h until the gelatin precipitated. The
supernatant was discarded and the sediment was re-dissolved in 25 ml
ultrapure water at 50 °C while stirring at 250 rpm for 30 min. Subse-
quently, the pH of the solution was adjusted to 2.5 by using con-
centrated HCl and a second desolvation step was performed by drop-
wise (0.1 ml/s) addition of 80 ml acetone at 50 °C while stirring at
1200 rpm. The crosslinking of the GNPs was accomplished by adding 25
(w/w)% glutaraldehyde (GA) solution. The amount of added GA was
adjusted such that the molar ratio between the NH2 groups of gelatin
and GA molecules was 1:1. Calculations were performed based on the
assumptions that MWgelatin = 100 kDa and 1 mol gelatin has 37 mol
NH2 [36]. The resultant suspension was stirred at 600 rpm for 16 h at
room temperature. Next, an equal volume of 100 mM glycine solution
was added to the suspension to block the unreacted GA and stop the
cross-linking reaction. The suspension was stirred for 1 h at room
temperature before being centrifuged at 7000 g for 1 h (Avanti™ J-20XP
centrifuge, Beckman Coulter, Brea, CA) to separate the GNPs from the
reaction mixture. The GNPs were rinsed with ultrapure water in three
rounds of centrifugation and resuspension. The obtained GNPs were
cationized to increase the positive surface charge and consequently
enhance the loading of OVA and poly(I:C). Briefly, the pH of GNP
suspension was adjusted to 4.5 and the quaternary amine cholamine
(10% of the weight of GNPs) was added under constant stirring. After
5 min, EDC (10% of the weight of GNPs) was added to the suspension to
activate the carboxylic groups of gelatin which would couple chola-
mine. The mixture was stirred for 3 h at room temperature. The ca-
tionized GNPs were purified by three successive centrifugation steps as
described above. Finally, the nanoparticles were resuspended in ultra-
pure water by using vortexing and probe sonication [37], and stored at
4 °C for further experiments.
To prepare OVA loaded GNPs (GNP-OVA) for the humoral response
study, 100 μg OVA in water was added to 2000 μg GNPs in water (total
volume 1 ml) and the samples were mixed for 1 h (400 rpm, 25 °C). For
OVA and poly(I:C) co-loaded GNPs (GNP-OVA-PIC), after shaking OVA
and GNPs for 1 h, 100 μg poly(I:C) (containing 1% rhodamine-labeled
poly(I:C)) was added to the GNP suspension and the suspension was
mixed for another 1 h. Finally, the loaded nanoparticles were separated
by centrifugation at 2800 g for 5 min, followed by re-suspension in de-
ionized water. For the cellular response study, a modification of the
method was required to allow administration of a higher dose. Instead
of water, 4 mM HEPES buffer (pH 7.4) was used for loading to control
the pH. For GNP-OVA the added amounts of GNPs and OVA were
6000 μg and 300 μg (in 1.5 ml), respectively, and for GNP-OVA-PIC, the
amounts of GNP, OVA and poly(I:C) were 7000 μg, 200 μg and 200 μg
(in 1.5 ml), respectively. The modification did not significantly change
the characteristics of nanoparticles.
2.3. Characterization of the nanoparticles
2.3.1. Particle size and zeta potential determination
The particle size and polydispersity index (PDI), and zeta potential
for all formulations were determined by dynamic light scattering and
laser doppler velocimetry, respectively, by using a Nano ZS® zetasizer
(Malvern Instruments, Worcestershire, U.K.). Particle size measure-
ments were performed in 10 mM PB (pH 7.4) (PLGA nanoparticles, li-
posomes and MSNs) or ultrapure water (GNPs), while for zeta potential
measurements samples were diluted in 5 mM HEPES buffer (pH 7.4).
2.3.2. Morphological characterization
Morphology of PLGA nanoparticles and GNPs was visualized by
using scanning electron microscopy (SEM, Nova NanoSEM, FEI,
Eindhoven, The Netherlands) with a voltage of 15 kV. Nanoparticles
were first freeze-dried and coated with a thin layer of carbon. MSNs
were visualized by transmission electron microscopy (TEM) using a
JEOL 1010 instrument (JEOL Ltd., Peabody, MA) with an accelerating
voltage of 70 kV. To prepare the samples, several droplets of MSN
suspension (1 mg/ml) were added on a copper grid, dried overnight and
coated with carbon. Liposomes were visualized by Cryo-EM. The sam-
ples were diluted to 5 mg/ml and drops of 3 μl were applied to 300
mesh EM grids with lacey carbon (Ted Pella, USA). Grids were trans-
ferred into an electron microscopy grid plunger (EM GP, Leica,
Germany) operated at room temperature and 100% humidity. The
sample was vitrified by removing excess liquid immediately followed
by plunging into liquid ethane and the plunge-frozen grids were stored
in liquid nitrogen until further use. Samples were inserted into a Gatan
626 cryo holder (Gatan, Pleasanton, CA). A Tecnai F20 microscope
(Thermo-Fisher, Eindhoven, The Netherlands) was operated at 200 kV
and the EM images were recorded at defocus values between 1 and
3 μm underfocus on a Gatan 4 k × 4 k CCD (Gatan, Germany).
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2.3.3. Determination of loading efficiency of OVA and poly(I:C)
To determine the loading efficiency of OVA and poly(I:C) in PLGA
nanoparticles, the nanoparticles were dissolved in a mixture of 15% (v/
v) DMSO and 85% (v/v) 0.05 M NaOH and 0.5% SDS. The amount of
OVA was quantified by the microBCA method following the manufac-
turer's instructions. The amount of poly(I:C) was determined by the
fluorescence intensity of rhodamine labeled poly(I:C) (λex 545 nm/λem
576 nm) with a plate reader (Tecan M1000, Männedorf, Switzerland).
The loading efficiency of OVA in liposomes, MSNs and GNPs was de-
termined by measuring its intrinsic fluorescence intensity (λex 280 nm/
λem 320 nm) with the Tecan M1000 plate reader in the supernatant
before and after the encapsulation (MSNs and GNPs) or in the pur-
ification filtrates (liposomes). The loading efficiency of poly(I:C) in
these nanoparticles was quantified similarly by measuring the fluores-
cence of its rhodamine labeled equivalent (λex 545 nm/λem 576 nm).
The encapsulation efficiency (EE) and loading capacity (LC) of OVA
and poly(I:C) in the nanoparticles were calculated as below:
= ×
M
M
EE% 100%loaded OVA poly I C
total OVA poly I C
( : )
( : ) (1)
= ×
+ +
M
M
LC% 100%loaded OVA poly I C
nanoparticles OVA poly I C
( : )
( : ) (2)
where Mloaded OVA/poly(I:C) represents the mass of loaded OVA or poly
(I:C), Mtotal OVA/poly(I:C) is the total amount of OVA or poly(I:C) added to
the formulations and Mnanoparticles + OVA + poly(I:C) is the total weight of
nanoparticles, OVA and poly(I:C).
2.3.4. In vitro release studies
To study the release of OVA and poly(I:C), the nanoparticles were
dispersed in PBS and shaken by using an Eppendorf thermomixer
(Nijmegen, The Netherlands) at 37 °C with a speed of 550 rpm. The
concentration for PLGA nanoparticles, liposomes, MSNs and GNPs after
the suspension was 3 mg/ml, 5 mg/ml (lipid concentration), 1 mg/ml
and 1.3 mg/ml, respectively. At predetermined time intervals, the tubes
were taken out of the shaker bath and centrifuged at 10000 g for 10 min
(PLGA nanoparticles and MSNs) or at 2800 g for 5 min (GNPs). A re-
lease sample of 600 μl was taken from the supernatant and replaced by
fresh release medium. In the case of liposomes, 300 μl sample was
collected to Vivaspin 500 concentrators. After the centrifuging (350 g,
30 min), the filtrate was collected and replaced with fresh medium. The
amount of released OVA and poly(I:C) were determined by intrinsic
fluorescence of OVA (λex 280 nm/λem 320 nm) and fluorescence of
rhodamine labeled poly(I:C) (λex 545 nm/λem 576 nm), respectively,
using a Tecan M1000 plate reader. The amount of released OVA in
PLGA nanoparticles was determined by the MicroBCA method.
2.4. Hollow microneedles and applicator
Hollow microneedles were prepared as described earlier [38].
Briefly, 4-cm pieces of polyimide-coated fused silica capillaries (Poly-
micro, Phoenix AZ, 375 μm outer diameter, 50 μm inner diameter) were
first filled with silicone oil in a vacuum oven (100 °C) overnight and
subsequently etched for 4 h in≥48% hydrofluoric acid. The polyimide
coating was removed from the etched ends of capillaries by dipping
them into heated (250 °C) sulfuric acid for 5 min.
A hollow-microneedle applicator was used to control the injection
depth and volume as previously reported [5]. A 100-μl syringe with an
inner diameter of 1.46 mm was used in conjunction with a syringe
pump (NE-300, Prosense, Oosterhout, The Netherlands) and silica ca-
pillaries. High-pressure resistant CapTite™ connectors were used to
connect the pump, syringe, capillaries and needles.
2.5. Immunization studies
Female BALB/c mice (H2d) and C57BL/6 mice (H2b) were used for
the antibody response and T-cell response study, respectively. The mice
were 7–8 weeks old at the beginning of the experiment. All the mice
were purchased from Charles Rivers (Maastricht, The Netherlands) and
were housed under standardized conditions in the animal facility of
Leiden Academic Centre for Drug Research of Leiden University.
Experiments were approved by the ethical committee on animal ex-
periments of Leiden University (Licence number 14176).
2.5.1. Antibody response study
BALB/c mice were anesthetized by intraperitoneal injection of ke-
tamine (60 mg/kg) and xylanize (4 mg/kg), which was followed by the
shaving of the injection site. At the same day mice (n = 8/group) were
immunized by an intradermal injection of 10 μl nanoparticles loaded
with 0.31 μg OVA, with or without approximately 0.31 μg poly(I:C), on
the flank of the mouse by using the applicator, as described above.
Solutions of 0.31 μg OVA, with or without 0.31 μg poly(I:C), were used
as controls. The injection depth was set to about 120 μm. In addition,
subcutaneous injection of 0.31 μg OVA (100 μl) was used as another
control. Mice were immunized on day 0 (prime), day 21 (1st boost) and
day 42 (2nd boost), and sacrificed on day 49. Before each immuniza-
tion, on the same day, a venous blood sample was collected from the
tail to measure the antibody responses. Before the sacrifice, the blood
sample was collected from the femoral artery.
2.5.2. T cell response study
OT-I (OVA-specific CD8+) and OT-II (OVA-specific CD4+) T cell
transferred C57BL/6 mice were used for the T cell response study. To
obtain OT-I and OT-II T cells, spleens of OT-I and OT-II transgenic mice
(CD45.1) were isolated and single cell suspensions were obtained by
forcing the spleens through a 70 um strainer. After erythrocyte deple-
tion with ammonium chloride, percentage of CD8+/Valpha2+ or
CD4+/Valpha2+ cells was determined by flow cytometry (BD
FACSCanto-II, San Jose, CA). An equivalent of 8000 OT-I and 56,000
OT-II cells were intravenously transferred through the tail vein into
C57BL/6 mice. Next day, the T cell transferred mice were immunized
with nanoparticle formulations. OVA and poly(I:C) solutions were used
as controls. Before the immunization, mice were anesthetized by iso-
flurane inhalation (induction 4–5% and maintenance 1%), which was
followed by shaving of the injection site. On the same day, mice
(n = 5/group) were immunized by three intradermal injections of
13.3 μl (totally 40 μl) formulation containing 5 μg OVA with or without
approximately 5 μg poly(I:C) on the flank of the mouse (two injections
on the right side, one injection on the left side) by using the hollow-
microneedle applicator as described above. 7 days after the im-
munization, venous blood sample was collected from the tail to analyze
the T cell response.
2.6. Determination of OVA specific IgG antibodies
OVA-specific antibodies were analyzed by a sandwich enzyme-
linked immunosorbent assay (ELISA) as described earlier [39]. Briefly,
wells of the 96 well-plates were first coated with 500 ng OVA for 1.5 h
at 37 °C. The plates were blocked by incubation with 1% (w/v) BSA for
1 h at 37 °C. After the blocking, appropriate three-fold serial dilutions
of mouse sera were applied to the plates and incubated for 1.5 h at
37 °C. Then the plates were incubated with horseradish peroxidase-
conjugated goat antibodies against IgG, IgG1 and IgG2a (1:5000 dilu-
tion) for 1 h at 37 °C. Finally, specific antibodies were detected by TMB.
The absorbance was measured at 450 nm (Tecan M1000) and the an-
tibody titer was determined as a log10 value of the mid-point dilution
of S-shaped dilution-absorbance curve of the diluted serum level.
2.7. CD4+ and CD8+ T cell responses
The erythrocytes of the blood sample (100 μl) were first lysed by
incubating samples with 3 ml lysis buffer for 6 min in ice, followed by
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addition of 5 ml cell culture medium. After the centrifugation (5 min,
500 g), the supernatant was discarded and the samples were suspended
in 5 ml FACS buffer. Next, samples were centrifuged and 200 μl of cell
suspension was added to the 96-well plate after discarding the super-
natant. The cell surfaces were stained by incubating the cells with
100 μl diluted (1:800) fluorescently labeled antibodies specific for
CD45.1 (eFluor450), CD4 (APC) and CD8α (PerCP) for 30 min (100 μl/
well). After 30 min incubation at 4 °C, the excess antibodies were wa-
shed by using FACS buffer. The cells were incubated with fixation and
permeabilization solution (BD Biosciences) for 10 min at 4 °C. Finally,
the cells were washed with FACS buffer and analyzed by flow cytometry
(BD FACSCanto-II, San Jose, CA). The data were analyzed by using
FlowJo software.
2.8. Statistical analysis
All the data of immunization studies were analyzed by one way
ANOVA with Bonferoni's post-test by using GraphPad Prism software
(version 5.02). The level of significance was set at p < 0.05.
3. Results
3.1. Physicochemical characterization of nanoparticles
Four different nanoparticle formulations (PLGA nanoparticles, li-
posomes, MSNs and GNPs) were developed and characterized in terms
of size, zeta potential, surface morphology, and loading and release
properties of encapsulated antigen and adjuvant. Physicochemical
characteristics of the nanoparticles are summarized in Table 1. Ac-
cording to DLS, PLGA nanoparticles and liposomes had an average
diameter between 120 nm and 170 nm with a PDI value below 0.1
(PLGA nanoparticles) and 0.3 (liposomes). MSNs and GNPs had a larger
diameter, ranging from 500 nm to 760 nm, and PDI values between 0.1
and 0.3. The electron microscopy images revealed a spherical shape of
PLGA nanoparticles, liposomes and GNPs, whereas MSNs had a rec-
tangular shape with mesochannels along the short axis (Fig. 1). The
estimated size based on electron microscopy images is consistent with
the size in Table 1 for PLGA nanoparticles and liposomes. MSNs had a
smaller particle size in TEM images than in DLS measurements, in-
dicating the presence of aggregates in these nanoparticle suspensions.
In the case of GNPs, particles are swelling in aqueous medium [40],
which may explain the smaller particle size in SEM images as compared
to DLS.
PLGA nanoparticles and MSNs had a negative zeta potential,
whereas liposomes and GNPs possessed a positive zeta potential. In
general, co-encapsulation of poly(I:C) did not substantially affect the
size, the PDI and zeta potential of the nanoparticles (Table 1). More-
over, both OVA and poly(I:C) were efficiently encapsulated into the
nanoparticles. The EE% of OVA reached> 60% for all nanoparticles
except LB-MSN-OVA-PIC (34%) (Table 1). Similarly, poly(I:C) had a EE
% higher than 60%, except for PLGA nanoparticles (13.9%). During the
development of the preparation process of the nanoparticles, the in-
troduced amounts of antigen and adjuvant were optimized to obtain
similar loading capacities of OVA and poly(I:C) for each delivery system
(Table 1).
3.2. In vitro release of OVA and poly(I:C) from nanoparticles
To determine the release properties of OVA or poly(I:C) from the
nanoparticles, the particles were dispersed in PBS and the released
amount of OVA or poly(I:C) was measured at regular time intervals
during one month (Fig. 2). PLGA nanoparticles slowly released OVA
and on day 30, approximately 13% and 20% of the encapsulated OVA
were released from PLGA-OVA and PLGA-OVA-PIC, respectively. Poly
(I:C) release followed the OVA release and approximately 20% of the
encapsulated poly(I:C) was released during one month. Liposomes re-
leased about 30% OVA on the first day, followed by a slow release to
40% during one month. Approximately 12% poly(I:C) was slowly re-
leased from liposomes during one month. MSNs showed a burst release
of approximately 40% OVA within the first 6 h, followed by a slower
and linear release phase from 40% to almost 100% in the subsequent
two weeks. The release of poly(I:C) was slower and only 30% poly(I:C)
was released from LB-MSN-OVA-PIC within 15 days. GNPs showed a
burst release of nearly all loaded OVA and poly(I:C) within 2 h, fol-
lowed by a slow release until 4 days.
3.3. Antibody responses after intradermal immunization
First, it was examined whether intradermal vaccination with solu-
tions or nanoparticles containing 0.31 μg OVA with or without poly(I:C)
(~0.31 μg) (Table 1) can induce antigen specific antibodies. The dose
of antigen was chosen based on a dose response study (data not shown).
As shown in Fig. 3, all groups, except the subcutaneous control of OVA
solution, showed a detectable total IgG response on day 21, and the
highest response was detected for the PLGA-OVA-PIC group (Fig. 3A).
The total IgG levels increased after the boost on day 21 (Fig. 3B) and 42
(Fig. 3C). All studied nanoparticle formulations and OVA or OVA-poly
(I:C) solutions gave similar total IgG responses, except for PLGA-OVA.
These nanoparticles showed significant weaker total IgG responses on
day 42 and 49, but co-encapsulation of poly(I:C) in PLGA nanoparticles
increased significantly total IgG titers to similar levels observed with
the other nanoparticle suspensions. In conclusion, the nano-
Table 1
Physicochemical characteristics of OVA/poly(I:C) loaded nanoparticles.
Nanoparticles Sizea (nm) PDIb ZPc (mV) EEd % LCe %
OVA Poly(I:C) OVA Poly(I:C)
PLGA-OVA 157 ± 7 0.060 ± 0.028 -18 ± 1 64.7 ± 4.8 – 6.9 ± 0.5 –
PLGA-OVA-PIC 160 ± 1 0.052 ± 0.019 −22 ± 4 76.7 ± 2.0 13.9 ± 4.2 2.7 ± 0.7 3.0 ± 0.9
Lipo-OVA 124 ± 15 0.152 ± 0.026 44 ± 2 97.0 ± 2.4 – 1.6 ± 0.1 –
Lipo-OVA-PIC 171 ± 9 0.270 ± 0.040 41 ± 1 92.1 ± 5.6 98.6 ± 2.3 1.5 ± 0.1 1.6 ± 0.1
LB-MSN-OVA 656 ± 5 0.280 ± 0.018 −33 ± 3 73.8 ± 5.7 – 15.6 ± 1.2 –
LB-MSN-OVA-PIC 603 ± 17 0.318 ± 0.040 −38 ± 3 34.4 ± 3.3 64.9 ± 14.6 7.9 ± 0.8 5.9 ± 1.3
GNP-OVA 507 ± 31 0.131 ± 0.116 21 ± 2 90.9 ± 14.2 – 4.3 ± 0.7 –
GNP-OVA-PIC 757 ± 235 0.320 ± 0.179 8 ± 12 96.8 ± 4.3 95.0 ± 4.4 3.5 ± 0.9 3.4 ± 1.0
Data are average ± SD of at least 3 independent batches.
a Size: Z-average in diameter.
b PDI: poly dispersity index.
c ZP: zeta potential.
d EE: encapsulation efficiency.
e LC: loading capacity.
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Fig. 1. Electron microscope images of nanoparticles. A)
Scanning electron microscopy (SEM) image of PLGA na-
noparticles; B) Cryo-EM image of liposomes; C)
Transmission electron microscopy (TEM) image of MSNs;
D) SEM image of GNPs.
Fig. 2. Release profiles of OVA (A) and poly(I:C) (B) from
PLGA nanoparticles (blue/spheres), liposomes (purple/
diamonds), MSNs (green/triangles) and GNPs (brown/
squares) in PBS at 37 °C. Open and closed symbols corre-
spond to poly(I:C)-containing and poly(I:C)-free nano-
particles, respectively. Data points represent mean ± SD,
n = 3. (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of
this article.)
Fig. 3. OVA-specific total IgG antibody titers measured in BALB/c mice on day 21 (A), day 42 (B) and day 49 (C). Bars represent mean ± SEM, n = 8. *p < 0.05, **p < 0.01,
***p < 0.001. All the formulations were injected intradermally, except the subcutaneous control of OVA solution (OVA S.C.). Groups without a bar showed titers below the detection
limit of the ELISA.
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encapsulation of OVA or co-encapsulation of OVA and poly(I:C) did not
lead to enhanced total IgG titers.
Next, the subtype IgG1 and IgG2a titers were determined (Fig. 4).
The IgG1 titers followed the trend of total IgG titers (Fig. 4A, C, E) and
similarly the encapsulation of OVA or co-encapsulation of OVA and poly
(I:C) did not increase the IgG1 response. However, the encapsulation of
OVA, and particularly co-encapsulation of OVA and poly(I:C), strikingly
increased the IgG2a response compared to OVA and poly(I:C) solution
(Fig. 4B, D, F) (except GNP-OVA-PIC). Furthermore, liposomes and
PLGA nanoparticles showed higher IgG2a responses than MSNs and
GNPs (Fig. 4F). Specifically, on day 21 only PLGA-OVA-PIC induced an
IgG2a response (Fig. 4B). After each boosting on day 21 (Fig. 4D) and
42 (Fig. 4F), there were more groups having an IgG2a response. On day
42, after prime and one boost, all OVA and poly(I:C) co-encapsulated
nanoparticles, except GNP-OVA-PIC, showed an IgG2a response
(Fig. 4D). After the second boost, on day 49, all the groups, except OVA
solution, induced a measurable IgG2a response (Fig. 4F). These results
illustrate that encapsulation of OVA, and especially co-encapsulation of
OVA and poly(I:C) in nanoparticles is critical for enhancement of IgG2a
response but the magnitude of this effect depends on the type of na-
noparticles.
3.4. T cell responses after intradermal immunization
The higher IgG2a responses observed with liposomes and PLGA
nanoparticles suggested that these formulations may be able to trigger
cellular immune responses more effectively. To study the efficacy of the
developed nanoparticle formulations to induce T cell mediated im-
munity in vivo, OT-I (OVA specific CD8+ T cells) and OT-II (OVA spe-
cific CD4+ T cells) cells were transferred into C57BL/6 mice before
Fig. 4. OVA-specific IgG1 (A, C, E) and IgG2a (B, D, F)
antibody titers measured in BALB/c mice on day 21 (A, B),
42 (C, D) and 49 (E, F). Bars represent mean ± SEM,
n = 8. *p < 0.05, **p < 0.01, ***p < 0.001. All the
formulations were injected intradermally, except the sub-
cutaneous control of OVA solution (OVA S.C). Groups
without a bar showed titers below the detection limit of the
ELISA.
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intradermal vaccination. Seven days after the immunization T cell re-
sponses in blood were analyzed by flow cytometry with gating strategy
shown in Fig. 5A. Lipo-OVA-PIC evoked significant higher CD8+ T cell
responses than OVA and poly(I:C) solution and the other nanoparticle
formulations (Fig. 5B), suggesting efficient induction of CTL responses
by liposomes. In general, nano-encapsulation of OVA or co-encapsula-
tion of OVA and poly(I:C) increased the CD8+ response compared to
OVA or OVA-poly(I:C) solution. In the case of CD4+ T cell response,
Lipo-OVA-PIC and LB-MSN-OVA-PIC induced the strongest response
(Fig. 5C). OVA loaded nanoparticles induced similar CD4+ response
compared to OVA solution. Poly(I:C) co-encapsulation slightly in-
creased CD4+ responses compared to OVA-loaded nanoparticles but
only in the case of liposomes the improvement was significant. Fur-
thermore, the Lipo-OVA-PIC formulation induced a significantly higher
CD4+ response than OVA and poly(I:C) solution.
4. Discussion
In recent years, nanoparticles have been intensively investigated as
vaccine delivery systems because of their advantages, such as protec-
tion of antigen from degradation, increased antigen uptake by dendritic
cells and the ability to co-deliver antigen and adjuvant [10,22,41].
Nanoparticles also offer the possibility to adjust the type of immune
response by modifying the nanoparticle characteristics such as size,
surface charge and antigen release profile [10]. Numerous studies have
indicated that nanoparticles can be used to modulate the immune re-
sponse [9,10,12,15,17,18,20,22,25,39,42]. Owing to its high density of
antigen-presenting cells, the skin could be an attractive site of admin-
istration of nanoparticulate vaccines. However, relatively little is
known about the effect of nanoparticulate vaccines after (microneedle-
mediated) intradermal vaccination. Therefore, in this study, we used
hollow microneedles together with an applicator to examine the effect
of nano-encapsulation of antigen and adjuvant on both the humoral and
cellular response in mice. Our results showed that antigen and adjuvant
loaded nanoparticles were successfully delivered intradermally in mice
by using hollow microneedles together with the applicator, leading to
an effective nanoparticle-dependent immune response. Furthermore,
after co-encapsulation of OVA and poly(I:C) into nanoparticles, the
immune response was modulated towards a Th1 direction.
Previously, the in-house developed hollow microneedle/applicator
system has been used for immunization with inactivated virus [4–6]. In
these studies, we used hollow microneedles with a bore diameter of
20 μm. However, the system has not been used with nanoparticles with
larger size (> 100 nm). Therefore, the injection of nanoparticles
through the system was tested in vitro (data not shown) prior to the in
vivo studies presented here. These pilot studies showed that the hollow
microneedles could be blocked due to occasional nanoparticle ag-
gregation if the bore diameter was 20 μm. By increasing the bore dia-
meter to 50 μm, this problem could be circumvented since increase of
the bore diameter decreases particle obstruction in the system.
Fig. 5. OVA-specific T cell responses. (A) An example of the flow cytometry gating strategy used to determine the T cell responses. Lymphocytes were gated on forward/sideward scatter,
followed by the exclusion of double or adhering cells. After pregating on CD4+ or CD8+ T cells, the percentage of respectively OT-II and OT-I were measured by gating on CD45.1+ cells.
OVA specific CD8+ (B) and CD4+ (C) responses of transferred OT-I and OT-II cells in mouse blood 7 days after the immunization (mean ± SEM, n = 5). *p < 0.05, **p < 0.01,
***p < 0.001.
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Consequently, there was no blockage or leakage of formulation during
the immunization studies. The success of intradermal injection was
confirmed by the formation of a bleb at the injection site after each
injection. Furthermore, no adverse effects, such as erythema or skin
induration, were observed at the injection site during the studies.
Intradermally administered OVA/poly(I:C) loaded nanoparticles did
not increase the total IgG response compared to administration of an-
tigen/adjuvant alone. These results indicate that the encapsulation of
OVA or co-encapulation of OVA and poly(I:C) is not required for a
strong IgG response following intradermal administration. This may be
caused by the efficient uptake of the free antigen/adjuvant by antigen-
presenting cells in epidermis and dermis (Langerhans cells and den-
dritic cells) and lymph nodes beneath the skin. Additionally, poly(I:C)
has been shown to strongly improve CD8 responses rather than IgG
responses [43–45]. In case of PLGA nanoparticles, PLGA-OVA showed
even a lower total IgG response than OVA alone. This may be due to a
change in the tertiary structure of OVA, either during preparation or in
the acidic environment of PLGA nanoparticles during the degradation
of the polymer after administration [46,47]. Furthermore, in the cur-
rent study the OVA dose was much lower (0.31 μg) compared to the
dose used in previous studies (e.g.≥5 μg) [27,42,48]. The low dose can
magnify the detrimental effect of partial OVA degradation in PLGA
nanoparticles.
Our results clearly show that co-delivery of the antigen and ad-
juvant in nanoparticles, increased significantly the IgG2a antibody re-
sponse compared to OVA/poly(I:C) solution. This indicates that the
nanoparticles skewed the immune response of the antigen more to-
wards a Th1 direction [39]. Interestingly, PLGA nanoparticles and li-
posomes induced higher IgG2a responses than GNPs and MSNs. There
are at least two possible underlying factors that may play a role. i) The
higher IgG2a response is in line with the slower release of OVA and poly
(I:C) from PLGA nanoparticles and liposomes. The sustained release can
allow the co-processing of adjuvant and antigen within the same an-
tigen-presenting cell, which is suggested to be crucial for a higher IgG2a
response [15,19,22]. Differences in release behavior of OVA/poly(I:C)
between the nanoparticles may stem from the differences in the loca-
tion of the antigen and adjuvant in nanoparticles and in the strength of
the interaction between antigen/adjuvant and the nanoparticle matrix.
On the one hand, in PLGA nanoparticles and liposomes the antigen/
adjuvant is mixed with nanoparticle precursors during synthesis, and
the antigen/adjuvant is expected to be localized inside the matrix of
PLGA nanoparticles or in the aqueous core layer of liposomes. There-
fore, it is likely that the antigen/adjuvant is mostly released after the
nanoparticles are taken up and processed by antigen-presenting cells or
degraded. On the other hand, with GNPs and MSNs the loading of an-
tigen/adjuvant is done post-synthesis through adsorption of the an-
tigen/adjuvant onto the surface of nanoparticles, presumably based on
electrostatic interactions. In addition, in MSNs interactions are ex-
pected to occur also between OVA/poly(I:C) and the stabilizing lipid
bilayer. Antigen and adjuvant loaded in MSNs and GNPs are sensitive to
environmental conditions, such as salts and endogenous proteins pre-
sent in the skin tissue, that can accelerate the release. As a result, the
release of antigen/adjuvant from MSNs and GNPs can be faster than
that from PLGA nanoparticles and liposomes, as suggested by the in
vitro release data. Premature release can consequently lead to separate
uptake and processing of antigen and adjuvant by different antigen-
presenting cells. ii) The size of PLGA nanoparticles and liposomes
(< 200 nm) is substantially smaller than that of MSNs and GNPs (above
500 nm). Although single MSNs had a size below 200 nm, as shown by
TEM images [33], DLS showed a larger diameter, indicating the ag-
gregation of MSNs. Smaller particles with a size below 200 nm are
expected to be more efficiently taken up by dendritic cells than bigger
particles [16]. Moreover, large nanoparticles (500–2000 nm) have been
shown to be mostly associated with dendritic cells at the injection site
after intradermal delivery, while small (20–200 nm) nanoparticles are
able to drain to lymph nodes and target there the dendritic cells [49].
Therefore, the higher IgG2a response induced by the OVA/poly(I:C)
loaded PLGA nanoparticles and liposomes could be due to their better
uptake by dendritic cells and faster trafficking to the lymph nodes.
As IgG2a levels merely give an indication of the extent of IFN-γ
induced isotype switching, we also directly assessed the capacity of
each type of nanoparticulate formulation to induce CD8+ and CD4+ T
cell responses in OT cell transferred mice. The number of transferred OT
cells was kept low as an excess of transgenic T-cells have previously
been shown to alter the T-cell response [50]. Our results showed that
the Lipo-OVA-PIC formulation showed an exceptional high capacity to
induce both CD8+ and CD4+ T cell responses, in line with the data
from previous studies [18,48]. The DOTAP based cationic liposomes
have been shown to be very effective for the induction of CTL responses
[9,12,18], as the cationic lipids promote the activation and maturation
of dendritic cells and subsequently the T cell priming. Moreover,
EggPC, the main lipid component of the present liposomes, has been
shown to facilitate antigen presentation by enhancing peptide binding
to MHC class II molecules [51]. So, the superior immune responses of
liposomes may be caused by the properties of the lipids.
As explained above, MSNs and GNPs may not be able to enhance the
immune response because of their fast release of OVA/poly(I:C) and
large size. In case of PLGA-OVA-PIC group, our data showed that the co-
encapsulation of OVA and poly(I:C) did not increase the T cell re-
sponses. This is in contrast to previous reports [12–14], which have
shown that the co-encapsulation of OVA and poly(I:C) in PLGA nano-
particles can induce a strong CTL response after intramuscular or sub-
cutaneous vaccination. This indicates that vaccine formulations that
provide potent immune responses after intramuscular or subcutaneous
administration, may be less suitable for intradermal delivery, re-
emphasizing the need for route-specific optimization of vaccine for-
mulations [12,18,42]. Furthermore, targeting of different skin layers
may also affect immune responses, as shown in previous studies
[52,53]. Nowadays, there is an increasing need of efficient Th1/CTL
immune response, for example, in therapeutic vaccinations for cancer
[13,17,45] and intracellular pathogens [14,21]. Our results indicate
that cationic liposomes are very promising nano-carriers to induce a
superior Th1/CTL immune response compared to the other nano-
particles following hollow microneedle-mediated intradermal admin-
istration.
5. Conclusions
OVA and poly(I:C) loaded PLGA nanoparticles, liposomes, MSNs
and GNPs were successfully developed and compared for hollow mi-
croneedle-mediated intradermal immunization in mice. The en-
capsulation of OVA and co-encapsulation of OVA and poly(I:C) induced
a strikingly higher IgG2a antibody response than OVA/poly(I:C) solu-
tion, but the type of nanoparticle has a major effect on response. PLGA
nanoparticles and especially cationic liposomes induced the highest
IgG2a, CD8+ T cell and CD4+ T cell responses, suggesting their su-
periority for intradermal vaccination. Finally, our study demonstrated
that the in house developed hollow microneedle/applicator system is an
excellent tool for nanoparticle-based intradermal vaccination and to
screen different intradermal vaccine formulations.
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